Mpox
(New Oct 2024!)

*On 14 Aug 2024, the World Health Organization (WHO) declared the current outbreak of clade (type) I mpox in the Democratic Republic of the Congo (DRC) and neighboring countries a Public Health Emergency of International Concern (PHEIC). This outbreak is new and distinct from the recent 2022 global mpox outbreak, which was caused by clade II, although symptoms are similar and preventive measures are the same. Continued spread is likely.
Mpox is spread from person-to-person through direct, skin-to-skin contact with rash, scabs, body fluid, and to a lesser extent by touching items previously in contact with the rash or body fluids (e.g. clothes, linens). Direct contact with infected wild animals in the DRC region may also result in disease transmission.
The public health control measures established in 2022 for mpox control remain effective. The JYNNEOS vaccine is available and recommended for personnel at high risk, to include travelers to clade I mpox impacted regions who anticipate high risk contact.
NMCFHPC assesses the risk to force from either clade of mpox as low.

CDC Mpox Health Alert -23 Sept 2024
WHO PHEIC Declaration- 14 Aug 2024
NMCFHPC PHEIC Fact Sheet

⛓ Links

Overview

Mpox is an infectious disease caused by the monkeypox virus (MPXV), which is in the same family of viruses that causes smallpox. Known primarily for its characteristic rash with lesions that scab over, the mpox rash can occur on hands (palms), feet (soles), chest, face, or on/near the genitals or anus. Mpox has routinely occurred in countries of central and west Africa since it was first described in 1950, with limited travel-related spread. Two distinct clades of the MPXV have been identified: clade I (typically in central Africa) and clade II (seen more commonly in west Africa). Since May 2022, clade II mpox has spread globally, primarily through sexual networks. Until recently, clade I has remained limited to central Africa. On 14 Aug 2024, the World Health Organization declared clade I mpox as a Public Health Emergency of International Concern (PHEIC) due to unprecedented spread both within the DRC and into surrounding countries.

Mpox is a zoonotic disease, with cases often found close to tropical rainforests where there are animals that carry the virus. The disease can also spread among humans through contact with bodily fluids, lesions on the skin or on internal mucosal surfaces, such as in the mouth or throat, respiratory droplets, and contaminated objects.

The 2022 worldwide clade II outbreak resulted in tens of thousands of cases in the U.S., and DoD reported over a thousand cases among active-duty military members. Most cases were in adult males who reported intimate physical contact with other males. This clade II mpox continues to circulate at low levels throughout the world and is most often sexually transmitted.

The current clade I outbreak in the Democratic Republic of the Congo (DRC) includes a newly emerged subclade of the virus, clade Ib. While historically clade I is more severe than clade II, specific details about the epidemiology, to include transmissibility and severity, of this new subclade of mpox are still being studied. Clade II mpox is also circulating at low levels, both globally and in the DRC region. All clade I cases to date have originated in DRC and neighboring countries in eastern and central Africa, but continued regional and travel-associated spread is likely.

Importantly, all known clades of mpox are spread through close or intimate contact with a person with mpox, direct contact with an infected animal or contact with contaminated objects (e.g. clothes or linens used by an infected person).

The public health control measures established in 2022 for mpox control remain effective. The JYNNEOS vaccine, available and recommended for personnel at high risk, is also effective. NMCFHPC modeling of shipboard spread, along with observation of recent shipboard cases, suggests the threat of mpox to Navy operations remains low; spread on a ship or operational unit is anticipated to be limited, and large outbreaks are not expected.

Preventive Medicine

Prevention

General risk reduction strategies:

Avoid close contact with people who are sick with signs and symptoms of mpox, including those with skin or genital lesions.   
Avoid contact with wild animals (alive or dead) especially small mammals, including rodents (rats, squirrels) and non-human primates (monkeys, apes).   
Avoid contact with contaminated materials used by people who are sick (such as clothing, bedding, or materials used in healthcare settings) or that came into contact with wild animals.   
Avoid eating or preparing meat from wild animals (bushmeat) or using products (creams, lotions, powders) derived from wild animals.

The clade II mpox outbreak that began in 2022 was primarily transmitted through sexual networks, and there is evidence that a large proportion of clade Ib mpox is also being spread through sexual contact. More information about sexual transmission may be found at:

NMCFHPC Mpox and Sexual Health Fact Sheet

CDC recommends two doses of the JYNNEOS vaccine, administered 28 days apart, for populations who, based on their occupational, sexual and travel history are at higher risk for exposure to mpox virus. Mpox vaccine is NOT recommended for the general public. Pre-travel mpox immunizations may be considered for travelers/deployers to areas experiencing transmission who have an increased risk of personal or occupational exposure. This may include animal handlers, veterinary personnel with animal contact, laboratory personnel, security personnel, medical personnel, civil engineers, special operations, and civil affairs personnel. Additionally, immunization should be considered for travelers to areas experiencing transmission who anticipate sexual contact with local populations or close physical contact with animals. DoD information on the JYNNEOS vaccine can be found here: DHA-IHD Mpox Vaccine Info Paper

Isolation

In operational environments, patients who are suspected mpox cases (see CDC mpox case definitions below) should be isolated and treated as probable or confirmed cases. When operationally feasible, isolate patients ashore. If a rash has not developed 5 days after prodromal symptoms, alternate diagnoses should be considered. Clinicians should seek assistance from the nearest MTF or cognizant NEPMU for support with isolation guidance as well as follow-on testing, prophylaxis, and treatment indications.

Home isolation is most often recommended during recovery from mpox, and should be continued until symptoms resolve, the scabs have fallen off, and a fresh layer of intact skin has formed. This could take 2-4 weeks. CDC Home isolation recommendations

Contact Tracing

As soon as a suspected case is identified (using current mpox case definition for a suspected case), contact tracing should be initiated.  This is particularly relevant for shipboard populations where lab testing may not be as easily accessible.  Mpox case definitions (including a case definition for clade I) are available from CDC:  Mpox Case Definitions | Mpox | CDC

Conduct a public health interview to elicit names and contact information for all high and intermediate risk contacts going back 4 days prior to illness onset and ending with the resolution of the illness (or the time of the interview if illness is not resolved). The CDC recommends using your state or county/local health department reporting form or CDC’s short case report form https://www.cdc.gov/poxvirus/monkeypox/pdf/sCRF-Short-Form.pdf for collecting information during patient interviews for probable and confirmed cases.

Management of Contacts

Exposure in both community and healthcare settings should be assessed to determine the risk of transmission and if post-exposure prophylaxis (PEP) is indicated. Assess exposure risk based on CDC’s risk assessment standards:

For community exposures, CDC risk assessment and recommendations can be found at Monitoring and Risk Assessment for Persons Exposed in the Community | Mpox | Poxvirus | CDC.
For healthcare setting exposures, CDC risk assessment and recommendations for healthcare settings can be found at Infection Control: Healthcare Settings | Mpox | Poxvirus | CDC.

Mpox vaccine is recommended as PEP to contacts with higher risk exposure to monkeypox virus and may be recommended for intermediate risk exposures. PEP vaccine is most effective if received within 4 days of exposure and should be administered as soon as possible up to 14 days after exposure. Mpox vaccine is also recommended for people with ongoing risk of mpox exposure. More information on Mpox vaccine indications can be found here: CDC Mpox Vaccination Guidelines

All contacts, regardless of level of exposure risk or vaccination status, should monitor for symptoms for 21 days after their last exposure. Symptom monitoring can be active (e.g., medical evaluates an exposed individual daily) or passive (e.g., exposed individual self-monitors and reports symptoms to preidentified medical contact). Monitoring should include assessment of temperature and skin examination for rash, including inside the mouth and in the genital and anal areas. Examination can be performed by the person themselves, a caregiver, or a healthcare provider.

Asymptomatic close contacts may return to work per Commander’s operational needs and risk tolerance.

Cleaning, Disinfection, and Laundry

Use disinfectant products that are registered by the EPA for Emerging Viral Pathogens, tier 1 (https://www.epa.gov/pesticide-registration/disinfectants-emerging-viral-pathogens-evps-list-q). Follow CDC guidance for home infection control and laundry handling CDC Guidance for Cleaning and Disinfection, including proper use of personal protective equipment.

Routinely clean and disinfect commonly touched surfaces and items such as counters, tables/furniture, handrails, and light switches. Persons with mpox should use separate bathrooms and toilets if possible; surfaces should be cleaned and disinfected after use in shared bathroom/toilet spaces. Infected persons should do their own laundry if possible. If Navy issued mesh laundry bags are used, bags should be washed along with clothing/bedding.

Surveillance and Reporting

Routine surveillance is one of the best ways to identify disease clusters or outbreaks. Monitor disease and injury surveillance for clusters of rashes, and investigate increased cases of rash for infectious causes. If an mpox case is suspected, enhance surveillance to identify other potential mpox cases through clinical record queries for other local patients presenting with rash.
Although mpox is currently not on the Armed Forces Reportable Medical Events list, the CDC recommends reporting of probable and confirmed cases within 24 hours to enable timely implementation of prevention measures and contact tracing. Mpox is a reportable event in DRSi.
Mpox CDC case definitions are updated here: Mpox Case Definitions | Mpox | CDC

Suspected, probable, or confirmed cases should be evaluated by local Preventive Medicine personnel, who can assist with reporting through DRSi and to local/state public health authorities. Cases in operational or training settings should also be referred to the cognizant Navy Environmental and Preventive Medicine Unit (NEPMU).
Additional information on DRSi can be found at https://www.med.navy.mil/Navy-Marine-Corps-Public-Health-Center/Preventive-Medicine/Program-and-Policy-Support/Disease-Surveillance/
Operational units without adequate internet access can seek assistance with reporting from the nearest Navy Environmental Preventive Medicine Unit: https://www.med.navy.mil/Navy-Marine-Corps-Public-Health-Center/Field-Activities/.

Consultation

NEPMUs can provide consultative assistance with contact tracing, mitigation, isolation measures, education, reporting and messaging. Contact information is available at NMCFHPC Field Activities

MTF infectious disease specialists and the DHA Immunization Healthcare Division (through a 24/7 answering service at 877-438-8222) can assist with clinical consultation, vaccine access, and treatment.

DoD Epidemiology and Selected Publications

McGee SA, Russell JA, Metcalf-Kelly M. Enhanced Mpox Outbreak Case Detection Among MHS Beneficiaries Through Use of ESSENCE. MSMR. 2023 May 20;30(5):4-8. PMID: 37535344. MSMR-May-2023-Mpox surveillance

Titanji BK, Eick-Cost A, Partan ES, Epstein L, Wells N, Stahlman SL, Devineni P, Munyoki B, Pyarajan S, Balajee A, Smith J, Woods CW, Holodniy M, Davey VJ, Bonomo RA, Young-Xu Y, Marconi VC. Effectiveness of Smallpox Vaccination to Prevent Mpox in Military Personnel. NEJM 2023 Sept 21; 389(12): 1147-1148

Bureau of Medicine and Surgery
7700 Arlington Blvd. Ste. 5113 Falls Church, VA 22042-5113
This is an official U.S. Navy website
This is a Department of Defense (DoD) Internet computer system.

General Navy Medical Inquiries (to Bureau of Medicine and Surgery): usn.ncr.bumedfchva.list.bumed---pao@health.mil